Should You Buy LogicBio Therapeutics Inc (LOGC) in Biotechnology Industry?

Monday, October 24, 2022 10:53 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy LogicBio Therapeutics Inc (LOGC) in Biotechnology Industry?

LogicBio Therapeutics Inc (LOGC) is near the top in its industry group according to InvestorsObserver. LOGC gets an overall rating of 90. That means it scores higher than 90 percent of stocks. LogicBio Therapeutics Inc gets a 100 rank in the Biotechnology industry. Biotechnology is number 14 out of 148 industries.

LOGC has an Overall Score of 90. Find out what this means to you and get the rest of the rankings on LOGC!

See Full LOGC Report

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With LogicBio Therapeutics Inc Stock Today?

LogicBio Therapeutics Inc (LOGC) stock has fallen -0.49% while the S&P 500 has gained 0.48% as of 10:45 AM on Monday, Oct 24. LOGC is down -$0.01 from the previous closing price of $2.06 on volume of 55,704 shares. Over the past year the S&P 500 is lower by -17.42% while LOGC is down -46.34%. LOGC lost -$0.16 per share the over the last 12 months. Click Here to get the full Stock Report for LogicBio Therapeutics Inc stock.